Sutro Biopharma (STRO) 2025 Conference June 04, 2025 11:05 AM ET Speaker0 Biotech in The US. It is my pleasure to have the fireside chat with our next company, Suture Biopharma CEO, Jane. Welcome. Speaker1 Thank you. Thank you, Greg. Thank you. It's great to be here. Speaker0 Awesome. Yes. So I know lots going on happening at Suture lately, and then more important is kind of a strategic reprioritization and then to focus on the real value of your very unique platform. Maybe we'll start from there. So with t ...

SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operations. “We are ...

Sutro Biopharma (STRO) FY Conference Summary Company Overview - **Company**: Sutro Biopharma - **Event**: TD Cowen's Sixth Annual Oncology Innovation Summit - **Date**: May 28, 2025 Key Points Strategic Changes - Sutro Biopharma conducted a strategic review to enhance shareholder value, leading to a focus on advancing their second and third generation Antibody-Drug Conjugates (ADCs) pipeline [3][4] - The development of Lavelta has been deprioritized, but insights gained will inform future product design and clinical strategies [4][5] ADC Pipeline Differentiation - Sutro claims to have one of the most powerful ADC technologies, optimizing every component from antibody to linker to payload [8] - The next generation ADCs are designed to target complex biological targets, utilizing both single and dual payloads [8][9] - Dual payload ADCs are expected to overcome resistance seen in single payload ADCs, providing targeted chemotherapy and combination therapy [9][10] Safety and Efficacy - Sutro's platform allows for higher dosing compared to competitors, with a therapeutic index that can be optimized for safety [10][12] - The company has seen significant preclinical data indicating a two to threefold higher pharmacokinetics (PK) compared to competitors, which may translate into better patient outcomes [24][25] - The manufacturing process in cell-free extracts avoids glycosylation, reducing potential toxicity [17][20] STRO-four Development - STRO-four is a tissue factor ADC with a DAR-eight exotecan and proprietary beta glue linker, designed to minimize on-target liabilities [39][40] - Sutro aims to file an Investigational New Drug (IND) application in the second half of 2025, with first-in-human studies expected by year-end [47] - The ADC is anticipated to have 50-fold higher exposure compared to the approved competitor, Tisotumab vedotin, which could lead to improved patient benefits [49][50] Future Programs - STRO-six, another ADC program, targets integrin beta-six and is expected to have a significant commercial opportunity, particularly in lung cancer [53] - The platform's ability to avoid interstitial lung disease (ILD) is highlighted as a critical factor for success in lung cancer treatments [55] Additional Insights - Sutro's approach to selecting payloads and linkers is data-driven, focusing on combinations that enhance therapeutic index while minimizing safety risks [35][36] - The company is exploring the potential for three payload combinations to further enhance treatment efficacy against resistant tumors [34] Conclusion - Sutro Biopharma is positioning itself as a leader in the ADC space with innovative technologies and a focus on safety and efficacy, aiming to address unmet needs in oncology treatments. The upcoming IND filings and clinical trials are critical milestones for the company.

Sutro Biopharma (STRO) 2025 Conference Summary Company Overview - Sutro Biopharma is focused on advancing its next-generation antibody-drug conjugates (ADCs) technology, aiming to differentiate from conventional ADCs and enhance commercial viability [3][4][5] Key Points and Arguments 1. **Strategic Reprioritization**: The company has deprioritized its late-stage program for loveltomab tazavibulin, focusing instead on a new pipeline strategy that emphasizes innovative ADCs [3][4] 2. **Next-Generation ADCs**: Sutro is developing ADCs targeting hard-to-reach targets, which are more complex and widely expressed across solid tumors, ensuring better commercial viability [4][5] 3. **Clinical Development Plans**: Sutro aims to deliver three Investigational New Drug (IND) applications over the next three years, starting with STRO-four in the second half of 2025, followed by STRO-six in 2026 and a dual payload ADC in 2027 [4][6] 4. **Innovative Technology**: The company claims to have one of the most powerful ADC technologies, optimizing every component of the ADC to achieve a wider therapeutic index [3][9] 5. **Dual Payload ADCs**: Sutro is focusing on dual payload ADCs, which have the potential to overcome resistance seen in single payload ADCs, providing a competitive edge in the market [6][24][25] 6. **Clinical Efficacy**: Preliminary data suggests that STRO-four has significantly higher exposure and antitumor activity compared to conventional ADCs, with a 17-fold increase in Cmax and a 50-fold increase in exposure at HNSCD [14][20] 7. **Target Selection**: The company emphasizes the importance of selecting patients based on target antigen expression, which enhances the likelihood of positive clinical outcomes [21] Additional Important Content 1. **Collaboration and Partnerships**: Sutro is collaborating with Astellas on dual payload ADCs, which is advancing rapidly and is seen as a significant opportunity for the company [26][29] 2. **Manufacturing Capabilities**: Sutro has developed a robust external CDMO network to improve cost efficiency and speed in ADC manufacturing, which supports its early pipeline [4][7] 3. **Competitive Landscape**: The ADC market is becoming congested, particularly with common targets like FR alpha, which may affect commercial viability; Sutro's focus on unique targets aims to mitigate this risk [5][6] 4. **Regulatory Simplicity**: The development of dual payload ADCs is seen as advantageous due to regulatory simplicity compared to combining multiple compounds [25][30] 5. **Pipeline Execution**: Sutro's leadership team, with extensive ADC oncology experience, is focused on executing the innovative pipeline and achieving key deliverables [31][32]

Sutro Biopharma, Inc. (STRO) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -44.44%. A quarter ago, it was expected that this company would post a loss of $0.86 per share when it actually produced a loss of $0.89, delivering a surprise of -3.49%.Over the last four quarters, the company has s ...

- Sharpened product candidate focus on its next-generation ADC portfolio, following strategic review and pipeline reprioritization - - Promising preclinical results with STRO-004 and dual-payload ADC, as well as STRO-006 programs presented at AACR 2025 and PEGS, respectively - - Three INDs for wholly-owned programs anticipated in next 3 years, beginning with potential best-in-class Tissue Factor ADC, STRO-004, planned for 2H 2025 - - IND-enabling toxicology study ongoing for one program within Astellas iADC ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-38662 SUTRO BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-0926186 (State ...

Exhibit 99.1 Sutro Biopharma Reports First Quarter 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., May 8, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2025 and recent business highlights. • In March, Sutro announced completion of a strategic portfolio review resulting in the prioritization of its wholly ...

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming investor conferences. Conference Details: The Citizens Life Sciences ConferenceDate: May 7-8, 2025Location: New York, NY BofA Securities 2025 Health Care ConferenceDate: May 13-15, 2025Location: Las Vegas, NV Webcasts of the pres ...

- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile -SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations will cover p ...